Corona Remedies Margin Trend — Quarter by Quarter
Corona Remedies's EBITDA margin moved from 21.7% in Q2 FY26 to 18.0% in Q4 FY26 across 3 quarters. Management commentary below explains the cost and pricing drivers mentioned on calls.
Corona Remedies's EBITDA margin moved from 21.7% in Q2 FY26 to 18.0% in Q4 FY26 across 3 quarters. Management commentary below explains the cost and pricing drivers mentioned on calls.